Patents Assigned to Biogen Idec Ma Inc.
-
Publication number: 20150168430Abstract: The present invention provides compounds of Formula (I) and (II): (I) (II) wherein R1, R2, R4, R5, R6, X and n are as defined herein, and wherein R3 is hydrogen or a sulfur protecting group. Compounds of Formula (I) and (II), wherein R is hydrogen, may be useful in methods for detecting a reactive metabolite in a sample, e.g., wherein the metabolite is generated from the metabolism of a test compound, and wherein the metabolite and the compound of Formula (I) or (II) react to form a detectable adduct, e.g., detectable by mass spectrometry.Type: ApplicationFiled: May 22, 2013Publication date: June 18, 2015Applicant: Biogen Idec MA Inc.Inventor: Natalia Penner
-
Publication number: 20150158929Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.Type: ApplicationFiled: July 11, 2012Publication date: June 11, 2015Applicants: AMUNIX OPERATING INC., BIOGEN IDEC MA INC.Inventors: Volker Schellenberger, Pei-Yun Chang, Fatbardha Varfaj, Sheng Ding, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, John Kulman, Tongyao Liu, Garabet G. Toby, Haiyan Jiang, Robert Peters, Deping Wang, Baisong Mei
-
Publication number: 20150152182Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.Type: ApplicationFiled: February 4, 2015Publication date: June 4, 2015Applicant: BIOGEN IDEC MA, INC.Inventors: Julie TAYLOR, Theodore A. YEDNOCK
-
Publication number: 20150139992Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.Type: ApplicationFiled: August 6, 2014Publication date: May 21, 2015Applicants: TOPOTARGET SWITZERLAND SA, BIOGEN IDEC MA INC.Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
-
Patent number: 9034324Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: GrantFiled: March 10, 2010Date of Patent: May 19, 2015Assignee: BIOGEN IDEC MA INC.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20150132259Abstract: The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.Type: ApplicationFiled: August 30, 2013Publication date: May 14, 2015Applicant: Biogen Idec MA Inc.Inventors: KoChung Lin, Blake Pepinsky, Ling Ling Chen, Donna M. Hess, Edward Y. Lin, Russell C. Petter, Darren P. Baker
-
Patent number: 9029359Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.Type: GrantFiled: September 3, 2010Date of Patent: May 12, 2015Assignees: Biogen Idec MA, Inc., Sunesis Pharmaceuticals, Inc.Inventors: Minna Bui, Patrick Conlon, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Alexey Ishchenko, Tracy J. Jenkins, Gnanasambandam Kumaravel, Doug Marcotte, Noel Powell, Daniel Scott, Art Taveras, Deping Wang, Min Zhong
-
Publication number: 20150125460Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: January 14, 2015Publication date: May 7, 2015Applicant: BIOGEN IDEC MA INC.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Patent number: 9011859Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.Type: GrantFiled: April 11, 2013Date of Patent: April 21, 2015Assignee: Biogen Idec MA Inc.Inventors: Linda C. Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
-
Patent number: 9005926Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: GrantFiled: October 1, 2010Date of Patent: April 14, 2015Assignee: Biogen Idec Ma Inc.Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas
-
Patent number: 8992924Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: GrantFiled: May 17, 2011Date of Patent: March 31, 2015Assignee: Biogen Idec MA Inc.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Publication number: 20150080840Abstract: The method described herein reduces the amount of aggregating metal released into solutions of Interferon-beta.Type: ApplicationFiled: July 21, 2014Publication date: March 19, 2015Applicant: BIOGEN IDEC MA INCInventors: Eric Anthony Faulkner, Mary Diana DeBiase
-
Publication number: 20150075261Abstract: In one aspect, the disclosure provides methods of distinguishing a glycosaminoglycan from one or more other components in a sample by subjecting the sample to size-exclusion chromatography using a mobile phase having a pH of 6.8 or lower. A mobile phase having a pH of 6.8 or lower is found to improve the separation of glycosaminoglycans from proteins during size exclusion chromatography. In some embodiments, improved separation is due to the low pH of the mobile phase causing elution of less dispersed fractions of the protein and/or glycosaminoglycan. In some embodiments, the overlap between protein and/or glycosaminoglycan fractions is reduced.Type: ApplicationFiled: April 11, 2013Publication date: March 19, 2015Applicant: Biogen Idec MA Inc.Inventors: Zoran Sosic, Andrew Blum, Bing Guan, Boris Boumajny
-
Patent number: 8980610Abstract: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.Type: GrantFiled: November 20, 2009Date of Patent: March 17, 2015Assignee: Biogen Idec MA Inc.Inventors: Keith Selvitelli, Justin McCue
-
Publication number: 20150071917Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.Type: ApplicationFiled: July 14, 2014Publication date: March 12, 2015Applicant: Biogen Idec MA Inc.Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Publication number: 20150064177Abstract: The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.Type: ApplicationFiled: August 27, 2014Publication date: March 5, 2015Applicant: BIOGEN IDEC MA INC.Inventors: Mary M. BENDIG, Olivier J. LEGER, Jose SALDANHA, Tarran S. JONES, Ted A. Yednock
-
Patent number: 8969042Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.Type: GrantFiled: March 26, 2014Date of Patent: March 3, 2015Assignee: Biogen Idec MA Inc.Inventors: Anthony Rossomando, R. Blake Pepinsky, BangJian Gong
-
Publication number: 20150056188Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.Type: ApplicationFiled: March 15, 2013Publication date: February 26, 2015Applicant: Biogen Idec MA Inc.Inventors: Kenneth Simon, Thomas Cameron, Mia Rushe, Justin Caravella, George Campbell Kaynor
-
Publication number: 20150056205Abstract: This invention relates generally to methods of treating inflammatory bowel diseases (IBD), asthma, Crohn's Disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid-sparing effective amount of an immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.Type: ApplicationFiled: July 28, 2014Publication date: February 26, 2015Applicant: BIOGEN IDEC MA INC.Inventor: Ivan LIEBERBURG
-
Patent number: 8961976Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: GrantFiled: December 19, 2013Date of Patent: February 24, 2015Assignee: Biogen Idec Ma Inc.Inventors: Herman Van Vlijmen, Alexey Lugovskoy, Karl Hanf